KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Inventory (2017 - 2025)

Aquestive Therapeutics has reported Change in Inventory over the past 9 years, most recently at -$1.7 million for Q4 2025.

  • Quarterly results put Change in Inventory at -$1.7 million for Q4 2025, down 75.44% from a year ago — trailing twelve months through Dec 2025 was $126000.0 (up 117.38% YoY), and the annual figure for FY2025 was $126000.0, up 117.38%.
  • Change in Inventory for Q4 2025 was -$1.7 million at Aquestive Therapeutics, down from -$241000.0 in the prior quarter.
  • Over the last five years, Change in Inventory for AQST hit a ceiling of $1.7 million in Q3 2022 and a floor of -$1.7 million in Q4 2025.
  • Median Change in Inventory over the past 5 years was $196500.0 (2021), compared with a mean of $185500.0.
  • Biggest five-year swings in Change in Inventory: skyrocketed 7054.17% in 2022 and later crashed 538.18% in 2025.
  • Aquestive Therapeutics' Change in Inventory stood at $1.2 million in 2021, then crashed by 180.34% to -$944000.0 in 2022, then skyrocketed by 67.16% to -$310000.0 in 2023, then plummeted by 215.16% to -$977000.0 in 2024, then plummeted by 75.44% to -$1.7 million in 2025.
  • The last three reported values for Change in Inventory were -$1.7 million (Q4 2025), -$241000.0 (Q3 2025), and $927000.0 (Q2 2025) per Business Quant data.